Small-Cell Lung Cancer – Unmet Need – Detailed, Expanded Analysis: Extensive-Stage Small Cell Lung Cancer (US/EU)
MARKET OUTLOOK
Extensive-stage SCLC is an incurable disease for which very few treatment options exist. Platinum-based chemotherapy was the standard of care for these patients until the approval of immune checkpoint inhibitors—Tecentriq (Roche/Genentech) and Imfinzi (AstraZeneca)—changed the treatment paradigm for extensive-stage SCLC patients. The combination of immune checkpoint inhibitors with platinum agents dominates the first-line setting, but the clinical benefit of these regimens is limited. Treatment options are scarce in the recurrent setting, where poorly efficacious chemotherapeutic agents are mostly used. Despite recent advances, there is an urgent need for more-effective therapies that improve extensive-stage SCLC patients’ outcomes.
QUESTIONS ANSWERED
- What are the treatment drivers and goals influencing medical oncologists’ prescribing decisions for extensive-stage SCLC?
- How do current therapies, such as Tecentriq and Imfinzi, perform on key clinical attributes for these patients? How satisfied are physicians with the available therapies?
- What are the greatest unmet needs in extensive-stage SCLC? What are the most attractive opportunities for novel therapies in this setting?
- What trade-offs across key clinical attributes and price are U.S. and European medical oncologists willing to make for a new therapy to treat first-line extensive-stage SCLC?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 61 U.S. and 30 European medical oncologists fielded in November 2022
Key companies: Roche, Genentech, AstraZeneca
Key drugs: Tecentriq, Imfinzi, cytotoxic chemotherapy
Table of contents
- Small-Cell Lung Cancer - Unmet Need - Detailed, Expanded Analysis: Extensive-Stage Small Cell Lung Cancer (US/EU)
- Executive summary
- Unmet need - Extensive-stage small-cell lung cancer - executive summary - February 2023
- Introduction
- Overview
- Methodology
- Rationale for treatment drivers and goals selection
- Rationale for drug selection
- Products / regimens for extensive-stage small-cell lung cancer and rationale for drug selection
- Treatment drivers and goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed medical oncologists' prescribing decisions in extensive-stage small-cell lung cancer
- Importance of efficacy attributes to prescribing decisions in extensive-stage small-cell lung cancer: United States
- Importance of efficacy attributes to prescribing decisions in extensive-stage small-cell lung cancer: Europe
- Importance of safety and tolerability attributes to prescribing decisions in extensive-stage small-cell lung cancer: United States
- Importance of safety and tolerability attributes to prescribing decisions in extensive-stage small-cell lung cancer: Europe
- Importance of convenience of administration attributes to prescribing decisions in extensive-stage small-cell lung cancer: United States
- Importance of convenience of administration attributes to prescribing decisions in extensive-stage small-cell lung cancer: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in extensive-stage small-cell lung cancer: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in extensive-stage small-cell lung cancer: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for extensive-stage small-cell lung cancer: United States
- Overall performance of key therapies for extensive stage small-cell lung cancer: Europe
- Mean overall performance of key therapies for extensive-stage small-cell lung cancer: United States and Europe
- Relative performance of key therapies for extensive-stage small-cell lung cancer across select efficacy attributes: United States
- Relative performance of key therapies for extensive-stage small-cell lung cancer across select efficacy attributes: Europe
- Relative performance of key therapies for extensive-stage small-cell lung cancer across select safety and tolerability attributes: United States
- Relative performance of key therapies for extensive-stage small-cell lung cancer across select safety and tolerability attributes: Europe
- Relative performance of key therapies for extensive-stage small-cell lung cancer across select convenience of administration attributes: United States
- Relative performance of key therapies for extensive-stage small-cell lung cancer across select convenience of administration attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in extensive-stage small-cell lung cancer
- Surveyed medical oncologistsu2019 satisfaction with the performance of key therapies for extensive-stage small-cell lung cancer on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed medical oncologistsu2019 satisfaction with the performance of key therapies for extensive-stage small-cell lung cancer on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key efficacy attributes in extensive-stage small-cell lung cancer: United States
- Surveyed medical oncologists' ascribed level of unmet need across key efficacy attributes in extensive-stage small-cell lung cancer: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key safety and tolerability attributes in extensive-stage small-cell lung cancer: United States
- Surveyed medical oncologists' ascribed level of unmet need across key safety and tolerability attributes in extensive-stage small-cell lung cancer: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key convenience of administration attributes in extensive-stage small-cell lung cancer: United States
- Surveyed medical oncologists' ascribed level of unmet need across key convenience of administration attributes in extensive-stage small-cell lung cancer: Europe
- Key findings: unmet need in extensive-stage small-cell lung cancer and related indications
- Surveyed medical oncologists' ascribed level of unmet need in extensive-stage small-cell lung cancer and related indications: United States
- Surveyed medical oncologists' ascribed level of unmet need in extensive-stage small-cell lung cancer and related indications: Europe
- Opportunity analysis
- Areas of opportunity in the extensive-stage small-cell lung cancer market and emerging therapy insights
- Opportunity: a novel therapy or regimen that extends overall survival
- Opportunity: a novel therapy that improves progression-free survival
- Opportunity: a novel therapy with better safety and tolerability
- Opportunity: a therapy that improves convenience of administration
- Areas of opportunity in the extensive-stage small-cell lung cancer market and emerging therapy insights
- Target product profiles
- Assessing drug development opportunities
- Target product profile methodology
- Attributes and attribute levels
- Assigned prohibitions for the conjoint module
- Attribute importance and part-worth utilities
- First-line extensive-stage small-cell lung cancer Target Product Profile: attribute importance
- Median overall survival (months)
- Median progression-free survival (months)
- Objective response rate (% of patients)
- Incidence of grade 3/4 hematological toxicities (% of patients)
- Incidence of any grade gastrointestinal toxicities (% of patients)
- Incidence of any grade immune-mediated toxicities (% of patients)
- Price per 21-day cycle
- Conjoint analysis-based simulation of a market scenario
- First-line extensive-stage small-cell lung cancer market simulation: share of preference of Target Product Profiles included in the market scenario
- First-line extensive-stage small-cell lung cancer market simulation: likelihood to prescribe Target Product Profiles included in the market scenario
- First-line extensive-stage small-cell lung cancer market simulation: Target Product Profiles included in the market scenario
- Appendix
- Key abbreviations
- Bibliography
- Executive summary
Charlotte Jago, Ph.D., Senior Healthcare Research & Data Analyst, Oncology. Dr. Jago is a pharmaceutical industry analyst with more than 18 years’ experience, preceded by 5 years of laboratory research in academia (Imperial College London) and industry (Celltech, now UCB). She wrote the flagship Cortellis Drugs to Watch reports in 2013, 2014, 2015, and 2019 and led the improvement in immuno-oncology coverage on the Cortellis Competitive Intelligence platform. She holds a Ph.D. in immunology, a first-class degree in pharmacology, and a postgraduate certificate in journalism.
Priyanka Sharma, M.B.A., Healthcare Research & Data Analyst, Oncology. Prior to joining this company, she was a knowledge management consultant with ZS Associates, where she was responsible for designing and conducting secondary research on disease markets and providing end-to-end support to pharmaceutical clients during products’ life cycle. She also worked at DelveInsight Business Research, where she conducted pharmaceutical market forecasting in multiple therapy areas for various clients. She holds a bachelor’s degree in pharmacy and an M.B.A. in pharmaceutical management from the University Institute of Applied Management Sciences at Panjab University in Chandigarh, India.